Illinois is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
Recruiting
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
Gender:
ALL
Ages:
Between 3 days and 2 years
Trial Updated:
02/07/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Respiratory Syncytial Virus Infections
Feasibility Testing a Meditation App for Professionals Working With Youth in the Legal System
Recruiting
This feasibility clinical trial aims to assess the feasibility of implementing a 1-month app-based meditation program with officers in the juvenile legal system and other professionals working directly with legal-involved youth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Anxiety, Depression, Burnout, Professional, Emotion Regulation
Dupilumab in the Treatment of Pediatric Alopecia Areata
Recruiting
This is a prospective, randomized, double-blind, placebo-controlled clinical trial. The study will take place at four sites. This trial will enroll a total of 76 children and adolescents with moderate to severe AA (affecting at least 30% of the scalp) at the time of screening with a targeted 61 participants completing through Week 48. All subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥200 and/or have personal and/o... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/06/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Alopecia Areata
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
Recruiting
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxo... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/06/2025
Locations: St. Jude Midwest Affiliate - Peoria, Peoria, Illinois
Conditions: Hodgkin Lymphoma
Hypofractionation (Radiation) Trial for Multiple Myeloma
Recruiting
This study if for people who have been diagnosed with multiple myeloma and their doctors are recommending radiation to help treat it. Typically, radiation consists of 2-3 weeks of external beam radiation therapy. Doctors leading this study would like to see if a shorter radiation course (i.e., hypofractionation) for pelvic radiation is safe for multiple myeloma. Because participants in this study will receive a shortened radiation course, each daily treatment dose that is delivered would be slig... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: The University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Multiple Myeloma
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Recruiting
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data. * Treatment Arm (Group 1) * Active Control Arm (Group 2) * Crossover Arm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Advocate Health System, Downers Grove, Illinois
Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
Recruiting
To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2025
Locations: Cook County Health, Chicago, Illinois
Conditions: Angina, Stable Ischemic Heart Disease
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Recruiting
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Prostate Cancer, Prostate Adenocarcinoma
MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
Recruiting
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/05/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: COPD
Breaking Sitting with High-intensity Interval Training for Brain Health
Recruiting
This trial will examine whether interrupting 3.5 hours of sitting every 30 min with 6 min high intensity interval training (HIIT) breaks compared to light intensity interval training (LIIT) will improve brain health in cognitively normal older adults. This trial will test the feasibility of HIIT breaks to sitting. It will also address several important but unanswered questions: (1) Does interrupting sitting with short HIIT breaks improve frontoparietal function? (2) Can interrupting sitting with... Read More
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
02/04/2025
Locations: University of Illinois at Urbana-Champaign, Urbana, Illinois
Conditions: Aging
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Recruiting
The purpose of this study is to learn about the impact that the services and programs provided by the Leukemia and Lymphoma Society have among patients with blood cancer, such as access to care, quality of life, and financial burden.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Hybrid Type I Effectiveness-Implementation Trial of Project nGage
Recruiting
The goal of this Hybrid Type I effectiveness-implementation trial is to test Project nGage, an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among young Black men and women ages 18-49.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/04/2025
Locations: Howard Brown Health, Chicago, Illinois
Conditions: HIV Seropositivity